Economic Dimensions of Personalized and Precision Medicine
Author
Abstract
Individual chapters are listed in the "Chapters" tab
Suggested Citation
Note: EH PR
Download full text from publisher
To our knowledge, this item is not available for download. To find whether it is available, there are three options:1. Check below whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
- Veenstra David L. & Mandelblatt Jeanne & Neumann Peter & Basu Anirban & Peterson Josh F. & Ramsey Scott D., 2020. "Health Economics Tools and Precision Medicine: Opportunities and Challenges," Forum for Health Economics & Policy, De Gruyter, vol. 23(1), pages 1-14, June.
Book Chapters
The following chapters of this book are listed in IDEAS- Ernst R. Berndt & Dana P. Goldman & John W. Rowe, 2018. "Introduction to "Economic Dimensions of Personalized and Precision Medicine"," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 1-7, National Bureau of Economic Research, Inc.
- Tomas J. Philipson, 2018. "The Economic Value and Pricing of Personalized Medicine," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 9-19, National Bureau of Economic Research, Inc.
- Manuel Hermosilla & Jorge Lemus, 2018. "Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 21-52, National Bureau of Economic Research, Inc.
- John A. Graves & Zilu Zhou & Shawn Garbett & Josh F. Peterson, 2018. "The Value of Pharmacogenomic Information," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 53-86, National Bureau of Economic Research, Inc.
- Ernst R. Berndt & Mark R. Trusheim, 2018. "The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 87-114, National Bureau of Economic Research, Inc.
- Amitabh Chandra & Craig Garthwaite & Ariel Dora Stern, 2018. "Characterizing the Drug Development Pipeline for Precision Medicines," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 115-157, National Bureau of Economic Research, Inc.
- Mark V. Pauly, 2018. "Cost Sharing in Insurance Coverage for Precision Medicine," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 159-184, National Bureau of Economic Research, Inc.
- Kristopher J. Hult, 2018. "Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 185-216, National Bureau of Economic Research, Inc.
- David H. Howard & Jason Hockenberry & Guy David, 2018. "Physicians’ Financial Incentives to Personalize Medicine," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 217-235, National Bureau of Economic Research, Inc.
- Jui-fen Rachel Lu & Karen Eggleston & Joseph Tung-Chieh Chang, 2018. "Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 237-272, National Bureau of Economic Research, Inc.
- Rebecca A. Pulk & Jove Graham & Frank R. Lichtenberg & Daniel Maeng & Marc S. Williams & Eric Wright, 2018. "The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 273-304, National Bureau of Economic Research, Inc.
- Philippe Gorry & Diego Useche, 2018. "Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies," NBER Chapters, in: Economic Dimensions of Personalized and Precision Medicine, pages 305-334, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- O3 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights
- L1 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberbk:bern-13. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.